Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Cancer Resectable Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

34 year–84 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Radically resected pancreatic adenocarcinoma (stage I-III)
Resected tumor tissues and matched blood cells available
Signed informed consent

Exclusion criteria

Pancreatic cancer except pancreatic adenocarcinoma
Non-radical resection

Treatment and study plan

Multigene panel for next-generation sequencing

Device

HLA-I genotyping based on next-generation sequencing for prognosis evaluation

Primary outcomes

Disease-free survival (DFS)

Time frame: 2 years

Comparison of DFS between patients with specific HLA-I genotypes or not

Sponsors and collaborators

Lead sponsor

BAIYONG SHEN

Other

Collaborators

GeneCast Biotechnology Co., Ltd.

Registry information

Official study title

Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

Important dates

Study start: 2018
Primary completion: 2020
Study completion: 2021
First posted: Aug 2, 2022
Registry last updated: Aug 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed